The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics by Mizrahi, Romina et al.
The relationship between subjective well-being
and dopamine D2 receptors in patients treated
with a dopamine partial agonist and full
antagonist antipsychotics
Romina Mizrahi1,2, David Mamo1,2, Pablo Rusjan1, Ariel Graﬀ1, Sylvain Houle1,2
and Shitij Kapur3
1 Centre for Addiction and Mental Health, PET Centre, Toronto, ON, Canada
2 Department of Psychiatry, Faculty of Medicine, University of Toronto, ON, Canada
3 Department of Psychological Medicine, Institute of Psychiatry, King’s College, London, UK
Abstract
Antipsychotic drugs produce unpleasant subjective experiences, which have been associated with
high levels of dopamine D2 receptor occupancy. Aripiprazole is a partial agonist antipsychotic, which is
hypothesized to produce a diﬀerent subjective experience proﬁle compared to standard D2 antagonist
antipsychotics. The aim of this study was to compare the eﬀect of D2 occupancy produced by a partial
agonist antipsychotic (aripiprazole) to that of antagonist antipsychotics (risperidone or olanzapine) on
the subjective well-being of patients. Subjective well-being was measured using the Subjective Well-
being under Neuroleptics Scale (SWN) and was related to dopamine D2 receptor occupancy using
[11C]raclopride PET. Patients that were switched to aripiprazole showed improvement in their subjective
well-being from 79.80 (S.D.=16.08) to 89.90 (S.D.=15.33), an eﬀect that was sustained for 6 months. This
sustained improvement was observed despite very high levels of DA D2 occupancy (82–99%), in contrast
to the eﬀects of antagonist antipsychotics on subjective well-being.
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Introduction
Antipsychotic medications have been the ﬁrst-line
treatment for psychosis in schizophrenia and other
psychotic disorders for nearly half a century; and the
most important predictor of clinical outcome is ad-
herence with antipsychotic medication (Karow et al.
2007). However, patients dislike taking the medi-
cations and usually stop them (Marder, 2005). In re-
cent years, the blockade of the dopamine (DA) system
has been associated with these adverse subjective
experiences (see Voruganti & Awad, 2004 for review).
In addition, a-methyl paratyrosine (AMPT) – an agent
which blocks tyrosine hydroxylase and decreases DA
levels temporarily – has been shown to produce re-
versible dysphoria, and decreases in happiness and
tiredness in healthy volunteers (Verhoeﬀ et al. 2001,
2003) and patients with schizophrenia (Voruganti et al.
2001). Further, it has been demonstrated that high
levels of dopamine D2 (DA D2) blockade are associ-
ated with dysphoric experiences (de Haan et al. 2003,
2004) or depression (Bressan et al. 2002) in patients
with psychosis treated with antipsychotic medica-
tions. Consistent with these observations, we recently
replicated these original ﬁndings and furthermore
implicated extrastriatal brain regions (temporal and
insular cortex) in subjective dysphoria produced by
risperidone or olanzapine (Mizrahi et al. 2007). Taken
together these data suggest that a disruption of the DA
system through antagonism of striatal and/or extra-
striatal DA D2 receptors may play an important role in
adverse subjective experiences attributed to antagonist
antipsychotics.
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Aripiprazole, a D2 partial agonist, diﬀers from
previous typical and atypical antipsychotics in its
molecular actions at the DA D2 receptors. Clinically
eﬀective antipsychotic doses of 10–30 mg/d aripipra-
zole in patients with schizophrenia show a low pro-
pensity for extrapyramidal side-eﬀects or prolactin
elevation (Burris et al. 2002; Kane et al. 2002) despite
very high D2 receptor occupancy (Mamo et al. 2007;
Yokoi et al. 2002). The eﬀect of aripiprazole on subjec-
tive well-being has not been previously investigated,
and given the impact of subjective well-being on ad-
herence to antipsychotic medication, we decided to
investigate the neurobiological underpinning of ari-
piprazole on subjective well-being. While the high D2
occupancy of aripiprazole might be expected to pre-
dict worse subjective experience, the partial agonist
proﬁle at D2 receptors might be expected to mitigate
this eﬀect.
Methods
The data collection was undertaken at the Centre for
Addiction and Mental Health (CAMH), Toronto and
was approved by the CAMH Review Ethics Board,
all subjects provided written informed consent. This
study included a group of patients willing to switch to
aripiprazole – a partial agonist antipsychotic (n=11),
and a comparison group of patients that had been on
stable doses of antagonist antipsychotics (olanzapine
or risperidone, n=11) for>4 months. Subjects partici-
pating in the aripiprazole arm of the study partici-
pated in a PET study designed to study the occupancy
proﬁle of aripiprazole on DA and serotonin receptors ;
details including antipsychotic switching procedures
have been previously reported (Mamo et al. 2007).
Brieﬂy, they were randomized to 10, 15, 20 or 30 mg
aripiprazole and then followed for 6 months. Clinical
evaluations as well as imaging analysis procedures
were comparable for both groups. However, a longi-
tudinal arm is only available for the partial agonist
group.
Diagnosis was conﬁrmed using the Mini Inter-
national Neuropsychiatric Interview. Given that the
aripiprazole group included a longitudinal arm, the
following clinical assessments were completed at
baseline and then weekly for the ﬁrst 4 wk, with a ﬁnal
visit at 6 months: Clinical Global Impression Scale
(CGI), Simpson–Angus Scale (SAS), Barnes Akathisia
Scale (BAS) and the Abnormal Involuntary Movement
Scale (AIMS). Subjective well-being was measured
with the Subjective Well-being under Neuroleptics
Scale (SWN) – short version, which has ﬁve subscales:
(a) mental functioning, (b) self-control, (c) emotional
regulation, (d) physical functioning, (e) social inte-
gration. Items are clearly formulated and easy to
understand so that even the most cognitively dis-
turbed patients are able to complete the questionnaire
within 5–10 min (Naber et al. 2001). The SWN – short
version has shown adequate psychometric properties
(Cronbach’s a-coeﬃcient 0.92; Naber et al. 2001). The
Positive and Negative Symptom Scale (PANSS; Kay
et al. 1987), was administered at baseline and at the
following 2 wk and 4 wk with a ﬁnal visit at 6 months.
For both groups the same psychopathological measures
were obtained the day of the PET scan.
Statistical analysis of the clinical data was per-
formed using repeated-measures analysis of variance
with mixed models for the longitudinal portion of
the study. Bonferroni-adjusted pair-wise comparisons
were used as post-hoc tests. General linear models were
used to relate the clinical variables with the PET data.
All statistical analyses are two-tailed with p<0.05.
All patients completed a [11C]raclopride scan at ex-
pected peak plasma levels of aripiprazole olanzapine
or risperidone (3–5, 6 and 2 h after the last pill respect-
ively), using a CPS-HRRT high-resolution neuro-PET
camera system (CPS Inc., USA) measuring radioac-
tivity in 207 brain sections with a thickness of 1.2 mm
each. Transmission scans using 137Cs were used to
correct for attenuation of the emission scans. A saline
solution of 10.09¡0.7 mCi [11C]raclopride with a
speciﬁc activity at time of injection of 1598¡350 mCi/
mmol was injected as a bolus into an intravenous
line placed in an antecubital vein. Emission data were
acquired in list mode during 60 min. PET scans for the
aripiprazole arm were carried out following at least
2 wk continuous aripiprazole treatment.
Subjects undertook a standard fast-spin echo with a
proton density image acquired on a 1.5 T Signa-GE
scanner. The regions of interest (ROI) were dorsal
caudate (DCA), dorsal putamen (DPU), ventral stri-
atum (VST) and cerebellum (Mawlawi et al. 2001),
which was used as reference region. Time–activity
curves (TACs) were obtained from the dynamic PET
images in native space with reference to co-registered
MRI image using the in-house software validated for
obtaining semi-automated delineation of ROIs (Rusjan
et al. 2006). In order to calculate receptor occupancy,
data obtained from age- and sex-matched healthy
controls (23 controls with [11C]raclopride), using the
same PET and MRI protocols, were used as an esti-
mate of the subjects’ unmedicated baseline. This ap-
proach is justiﬁable as previous studies have not
shown a major eﬀect of illness on [11C]raclopride non-
displaceable binding potential (BPND) (Farde et al.
1987). BPND were obtained using the Simpliﬁed
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Reference Tissue Model (SRTM; Lammertsma &
Hume, 1996). Occupancy was calculated using the
following formula:
(BPND, controlxBPND,drug scan)=BPND, controlr100:
Results
Twenty patients with a diagnosis of schizophrenia
and two with schizoaﬀective disorder participated in
the present study. Eleven patients were switched to
aripiprazole and 11 patients had been taking either
risperidone or olanzapine for>4 months at the time of
the PET scan. The DA partial agonist antipsychotic
(aripiprazole) group had a mean age of 31 yr (S.D.=
6.89 yr), and the antagonist antipsychotic group had a
mean age of 36 yr (S.D.=7.03 yr) (t=1.8, d.f.=20,
p=0.08). Before the switch to aripiprazole, patients
were either oﬀ medication (t=2), on risperidone (t=5,
3–6 mg/d), olanzapine (t=3, 10–15 mg/d), or cloza-
pine (t=1, 100 mg/d). At the time of the PET scan
there was no diﬀerence between the groups for any of
the psychopathological measures (PANSS positive:
t=0.14, d.f.=20, p=0.88; PANSS negative: t=1.8,
d.f.=20, p=0.08; PANSS general : t=0.6, d.f.=20,
p=0.55; PANSS total : t=1.01, d.f.=20, p=0.32).
However, the groups diﬀered in their akathisia score
(t=x2.23, d.f.=20, p=0.03), with the aripiprazole
group showing more akathisia than the antagonist
antipsychotic group (side-eﬀects discussed in detail in
Mamo et al. 2007). Some patients in the antagonist
antipsychotic group (t=2) were concomitantly taking
benzodiazepines. The average dose of aripiprazole
was 18.75 mg (S.D.=7.72), and the dosages for olanza-
pine and risperidone were 17.85 mg (S.D.=7.83) and
1.87 mg (S.D.=0.88), respectively.
Within the study period (6 months) SWN total score
signiﬁcantly improved (F=6, d.f.=5, 47, p=0.0002),
with the main eﬀect observed during the ﬁrst week
(t=44.37, d.f.=47, Bonferroni adjusted p=0.001) and
remained unchanged at 6 months (Fig. 1). PANSS
positive score did not change at any time during
the study period (F=2.04, d.f.=3, 29, p=0.13), and
PANSS negative initial improvement was not sus-
tained at 6 months (F=1.75, d.f.=3, 29, p=0.17).
However, PANSS general signiﬁcantly improved in-
itially and was maintained at 6 months (F=5.38,
d.f.=3, 29, p=0.004) (see Table 1).
The measured D2 occupancies for the aripiprazole-
treated patients ranged from 82% to 99%. However,
the range of those treated with antagonist anti-
psychotics ranged from 57% to 89%. Aripiprazole
showed higher occupancy in all regions of the stri-
atum than antagonist antipsychotics (see Table 2).
SWN total score was not associated with striatal D2
occupancy in those treated with aripiprazole in any
subregion of the striatum (r=x0.43, p=0.18; r=0.01,
p=0.96; r=x0.52, p=0.09 for the DCA, DPU, VST,
respectively). As expected, striatal D2 occupancy was
signiﬁcantly associated with those treated with antag-
onist antipsychotics in the VST (r=x0.63, p=0.04),
but not associated in the DPU (r=x0.55, p=0.07) or
DCA (r=x0.50, p=0.11) (Fig. 2).
Since occupancy is a derived measure, i.e. it is ob-
tained after correcting individual measured BPND for
estimated baseline levels, we wanted to examine if the
BPND data from patients also correlated with SWN.
The data showed that SWN total score was signiﬁ-
cantly associated with VST BPND (r=0.63, p=0.04),
but not with the DCA (r=0.50, p=0.11) or DPU BPND
(r=0.55, p=0.07) of those treated with antagonist
antipsychotics. Similar to the occupancy data there
was no signiﬁcant association between SWN and
BPND in those treated with aripiprazole in any region
(r=x0.41, p=0.20; r=x0.01, p=0.95; r=x0.47,
p=0.14 for the DCA, DPU, VST, respectively). These
results are consistent with the occupancy data.
Discussion
To our knowledge this is the ﬁrst study to investigate
subjective well-being with aripiprazole (or any other
partial agonist) and its association with D2 receptor-
binding potentials and occupancy. First, we report a
putative early and sustained improvement in subjec-
tive well-being in patients switched to aripiprazole.
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Fig. 1. Subjective Well-being under Neuroleptics Scale (SWN)
score following the initiation of aripiprazole compared to
SWN score in the full antagonist antipsychotic group.
Subjective well-being change as indexed by the SWN total
score following the initiation of partial agonist (aripiprazole;
–$–), and full antagonist (–#–) antipsychotic groups.
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Second, in contrast to antagonist antipsychotics (de
Haan et al. 2000, 2003, 2004, 2005) aripiprazole did not
induce dysphoric eﬀects even at very high levels of D2
occupancy. Third, while the antagonist antipsychotics
showed an inverse relationship between occupancy
and SWN, aripiprazole did not.
The discussion presented herein needs to be
understood within the limitations imposed by the
design of the present study. First, we do not have
subjects’ own baseline PET data which introduces
some error in the estimated occupancy. However, we
present concordant ﬁnding with the BPND estimates
and sex- and age-corrected occupancy values, and
hence this should not detract from the conclusions
drawn in this study. Second, the sample size in each
subgroup was small. However, previous data that in-
vestigated the correlations between either AMPT- or
antipsychotic-induced dysphoria showed eﬀects that
ranged from r=0.53 (de Haan et al. 2000) to r=0.82
(Voruganti et al. 2001). Using the standard 80% power
and the conventional reliability to reject the null hy-
pothesis (i.e. p<0.05), the present study’s sample was
adequate to detect a signiﬁcant correlation between
those ranges. In fact, the signiﬁcant association be-
tween D2 BPND and occupancy data with SWN found
in the antagonist antipsychotic group can be seen as
replication from earlier SPECT and PET studies (de
Haan et al. 2000, 2003, 2004; Mizrahi et al. 2007).
Finally, the subjective well-being improvement pre-
sented herein could be viewed in light of a sample
selection bias. Aripiprazole is not marketed in Canada,
and the potential hope among patients receiving a
‘special ’ drug not otherwise available, may have in-
ﬂuenced our results. Importantly, subjects were not
randomized to treatment groups, possibly biasing the
clinical results of the present study. However, the
SWN scores were still elevated and stable at 6 months,
so that even if this was a placebo eﬀect, the eﬀect
was certainly sustained. Future studies should use a
blinded randomized design and careful monitoring of
medication adherence (i.e. with serum aripiprazole
concentrations (Gru¨nder et al. 2008) to properly test
the clinical ﬁndings of the present study. Finally,
patients were blind to their occupancies and BPND and
Table 1. Clinical measures following the switch to aripiprazole
Measures
Initial
visit (S.D.) 4 wk aripiprazole (S.D.)
Statistical analysis
(mixed models)
CGI 3.33 (0.94) 2.9 (0.79) F=1.78 d.f.=22.3 p=0.17
PANSS
Total 51.4 (12.44) 42.75 (8.10) F=10.58 d.f.=21.2 p=0.0007
Positive 12.50 (5.28) 10.45 (10.23) F=2.84 d.f.=21.2 p=0.08
Negative 12.33 (3.72) 9.18 (2.89) F=7.31 d.f.=21.2 p=0.003a
General 27.58 (7.31) 21.63 (4.00) F=11.26 d.f.=21.2 p=0.0005
SAS 0.25 (0.86) 0.41 (0.90) F=1.59 d.f.=44.4 p=0.19
BAS 0.41 (1.44) 1 (1.4) F=2.51 d.f.=44.4 p=0.05
SWN(T) 79.80 (16.08) 89.90 (15.33) F=7.33 d.f.=39.4 p=0.0002
CGI, Clinical Global Impression Scale; PANSS, Positive and Negative Symptom
Scale; SAS, Simpson–Angus Scale; BAS, Barnes Akathisia Scale; SWN(T),
Subjective Well-being under Neuroleptics Scale (Total score).
a Improvement not maintained at 6 months.
Table 2. Occupancy values for the antagonist and partial agonist antipsychotic
groups
Measures
Antagonist
antipsychotic (S.D.)
Partial agonist
antipsychotic (S.D.) Statistic (t, p)
Occupancy DCA 76.54 (8.99) 93.53 (5.55) x5.18,<0.001
Occupancy DPU 74.82 (9.39) 87.11 (3.57) x4.01, 0.001
Occupancy VST 76.26 (9.34) 91.65 (3.59) x5.05,<0.001
DCA, Dorsal caudate; DPU, dorsal putamen; VST, ventral striatum.
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thus could not have inﬂuenced the PET results pre-
sented.
The principal ﬁnding of this study is the obser-
vation of a signiﬁcant improvement in subjective
well-being, notwithstanding very high striatal DA D2
occupancy. This contrasts with previous and present
data on a series of antagonist antipsychotics : risper-
idone, olanzapine, and haloperidol (de Haan et al.
2000, 2003, 2004, 2005). The lack of relationship be-
tween DA D2 occupancy and SWN may be related to
the limited range of D2 occupancy or may be due to the
diﬀerential eﬀects of partial vs. full antagonists on DA
transmission. The more likely explanation is that in
contrast to full antagonists (Bressan et al. 2002; de
Haan et al. 2003, 2004; Mizrahi et al. 2007) a D2 partial
agonist antipsychotic would be expected to allow
for physiological DA function and consequently may
avoid adverse subjective experience and dysphoria
and possibly even improve subjective experience,
despite very high DA D2 occupancy. Precisely how a
partial agonist may decrease DA transmission to im-
prove psychosis, and not impede transmission rel-
evant for subject well-being is not clear. However, in
animal studies it has been shown that a partial agonist
like aripirazole had a much higher ability to block
amphetamine-induced locomotion (a measure of ab-
normal DA transmission) rather than spontaneous
locomotion (a measure of endogenous and normal DA
transmission) (Natesan et al. 2006). Thus, DA partial
agonist as well as the novel DA stabilizers may bring a
distinctive (beneﬁcial) eﬀect on subjective well-being.
In the present study we also replicated earlier re-
ports of the association between striatal D2 occupancy
and SWN using SPECT (de Haan et al. 2000, 2003,
2004) and PET (Mizrahi et al. 2007). The present results
are also consistent with the studies that have shown
that disruption of the DA function (temporarily, i.e
with AMPT) produce dysphoria, decrease happiness
and provoke tiredness in healthy volunteers (Fujita
et al. 2000; Verhoeﬀ et al. 2003) and in drug-free
schizophrenia patients (Voruganti et al. 2001). We
extend those initial ﬁndings by conﬁrming that the
ventral portion of the striatum was shown to have a
speciﬁc association with subjective well-being. The
motor side-eﬀects of antipsychotics are typically as-
sociated with the dorsal region of the striatum (Deutch
et al. 1996). We ﬁnd that the dysphoric eﬀects correlate
more speciﬁcally with the ventral portion of the
striatum. This latter region is considered part of the
‘limbic’ circuitry and can be plausibly linked to a role
in subjective well-being. The ventral portion of the
striatum (which is thought to be the analogue of the
nucleus accumbens in animals) is directly implicated
in reward and motivation (Wise, 2002) and is key to
many of the non-motor actions of antipsychotics in
animals (i.e. conditioned avoidance response models)
(Arnt et al. 1997). It is well documented that increased
DA release in the nucleus accumbens is associated
with the rewarding eﬀects accompanying the acute
administration of most drugs of abuse (Drevets et al.
2001). This putative dissociation between the associ-
ation of the dorsal and ventral portion of the striatum
BPND and occupancy data with subjective well-being
may be related to the diﬀerential DA receptors distri-
bution (i.e D2 predominates in the dorsal portion of the
striatum, while D3 in the most ventral portion), and
may be key in the development of new antipsychotics
(Sokoloﬀ et al. 1990).
In conclusion, the present data suggests that ari-
piprazole may be associated with early and sustained
improvement in subjective well-being, notwithstand-
ing the very high D2 occupancy. This may be related
to its partial agonist proﬁle at D2 receptors. Given
these ﬁndings, future controlled clinical studies, with
aripiprazole and the other newly emerging partial
agonists (e.g. bifeprunox), should make an eﬀort to
include subjective outcome as a variable of interest,
particularly as it has recently been suggested that early
improvement of subjective well-being is related to re-
mission in ﬁrst-episode schizophrenia (de Haan et al.
2008).
Ventral striatum occupancy (%)
50 60 70 80 90 100
S
W
N
 t
o
ta
l s
co
re
65
70
75
80
85
90
95
100
105
110
115
Fig. 2. Association between Subjective Well-being under
Neuroleptics Scale (SWN) score and [11C]raclopride DA D2
occupancy in partial agonist-treated (aripiprazole;#) vs. full
antagonist antipsychotic-treated (risperidone or olanzapine;
m) patients. No signiﬁcant correlation between SWN score
and D2 occupancy value at the ventral striatum with partial
agonist-treated patients; however, as expected, we found a
negative association between DA D2 occupancy in the ventral
striatum and SWN in patients treated with antagonist anti-
psychotics.
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